3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
27
Triple Negative Breast Neoplasms
9
Sarcoma
5
Neoplasm Metastasis
4
Liposarcoma
3
Urinary Bladder Neoplasms
2
Leiomyosarcoma
2
Inflammatory Breast Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Refractory Solid Tumors
1
Recurrence
1
Metastatic HER2-positive Breast Cancer
1
Inoperable Locally Advanced HER2-Negative Breast Cancer
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
HR+HER2- Breast Cancer
1
HER2-low Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Colorectal Neoplasms
1
Brest Cancer
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Interventions
Cyclophosphamide
12
Specimen Handling
9
cabozantinib
8
X-Rays
8
Magnetic Resonance Spectroscopy
8
fludarabine
7
Phantoms, Imaging
7
Biopsy
7
Temozolomide
6
Gemcitabine
5
regorafenib
4
pembrolizumab
4
Vincristine
4
Nuclear Medicine Department, Hospital
4
Nivolumab
4
Methotrexate
4
Doxorubicin
4
olaparib
3
irinotecan sucrosofate
3
fludarabine phosphate
3
dinutuximab
3
Zoledronic Acid
3
Surveys and Questionnaires
3
Irinotecan
3
Ifosfamide
3
Cisplatin
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Osteosarcoma
×
eribulin
×
1 year
×
Clear all
No trials found.